By Paul Armentano, NORML Deputy Director
The 2015 updated edition includes two additional disease profiles (Parkinson’s disease and PTS) and includes summaries of an additional 50+ relevant clinical and/or preclinical trials specific to cannabinoids’ therapeutic utility. Several existing sections, such as Chronic Pain, Diabetes, and Epilepsy, have been significantly expanded since the last edition (January 2013). Also updated is the Introduction to the Endocannabinoid System (authored by Dustin Sulak, DO) and Why I Recommend Medical Cannabis (authored by Estelle Goldstein, MD).
With summaries and citations of well over 250 recent peer-reviewed studies, this updated publication is one of the most thorough and up-to-date source-books available specific to documenting the established therapeutic qualities of cannabis. The updated publication is available online here.
Individual sections of this publication may be accessed at the links below:
Introduction to the Endocannabinoid System
Why I Recommend Medical Cannabis
Amyotrophic Lateral Sclerosis
Human Immunodeficiency Virus
Methicillin-resistant Staphyloccus aureus (MRSA)